A phase i and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 128-137

  Goyal, Lipika ^a,c   Wadlow, Raymond C ^d   Blaszkowsky, Lawrence S ^a,c   Wolpin, Brian M ^b,c   Abrams, Thomas A ^b,c   McCleary, Nadine Jackson ^b,c   Sheehan, Susan ^a   Sundaram, Eamala ^a   Karol, Michael D ^e   Chen, John ^e   Zhu, Andrew X ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Virginia Cancer Specialists   (United States)

^e Synta Pharmaceuticals Corp   (United States)

Author keywords

Ganetespib; Heat shock protein inhibitors; Hepatic dysfunction; Hepatocellular carcinoma; Pharmacokinetics; Phase I; STA 9090

Indexed keywords

GANETESPIB; SORAFENIB; HEAT SHOCK PROTEIN 90; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; ASIAN; BODY WEIGHT DISORDER; CANCER GROWTH; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ECOG STATUS; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOOT EDEMA; FUNCTIONAL STATUS ASSESSMENT; HEADACHE; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INJECTION SITE EXTRAVASATION; INSOMNIA; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MILD HEPATIC IMPAIRMENT; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTIC SHOCK; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; LIVER; LIVER DISEASE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZOLES;

EID: 84922070943     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0164-8     Document Type: Article

References (37)

1. Ferlay, J., GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase [Internet]. International Agency for Research on Cancer: Lyon, France, 2010; Vol. No. 10
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-90
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
4. Qin S, Bai Y, Ye S, Al E (2010) Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 28
5. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069-75
6. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479-83
7. Cheng A (2011) Phase III trial of sunitinib (Su) versus Sorafenib (So) in advanced hepatocellular carcinoma (HCC). In 2011 ASCO Annual Meeting, J Clin Oncol Vol. 29
8. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL (2013) Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517-24
9. Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens F, Qian J, McKee MD, Ricker JL, Carlson DM, El Nowiem S (2012) Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 30: (suppl 34; abstr 249)
10. Zhu AX, RO, Evans J, et al (2012) SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). In 37th Annual European Society for Medical Oncology Congress, Vienna, Austria
11. Izzo, C., Ramucirumab Misses Primary Endpoint in Phase III HCC Trial. 2014
12. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom Sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509-16
13. Zhu AX, Kudo M, Assenat E, Cattan S, Kang Y-K, Lim HY, Poon RTP, Blanc J-F, Vogel A, Chen C-L, Dorval E, Peck-Radsavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud KP, Anak O, Sellami DB, Chen L-T (2014) In EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after Sorafenib. Gastrointestinal Cancers Symposium, San Francisco, CA, JCO, San Francisco
14. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-49
15. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761-72
16. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796-801
17. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 93:14536-41
18. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F (2005) Role of HSP90, CDC37, and CRM1 as modulators of P16 (INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 42:1310-9
19. Lee CL, Hsiao HH, Lin CW, Wu SP, Huang SY, Wu CY, Wang AH, Khoo KH (2003) Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 3:2472-86
20. Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y (2012) The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells. Cell Biol Int 36:893-9
21. Wang, X.; Wang, S.; Liu, Y.; Ding, W.; Zheng, K.; Xiang, Y.; Liu, K.; Wang, D.; Zeng, Y.; Xia, M.; Yang, D.; Wang, Y., The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: The role of ER stress. Biochem Biophys Res Commun 2014.
22. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475-84
23. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA (2013) Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 3:430-43
24. Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Leiblich, C. W.; Fasano, J.; Moynahan, M. E.; D'Andrea, G.; Lim, K.; Reddington, L.; Haque, S.; Patil, S.; Bauman, L.; Vukovic, V.; El-Hariry, I.; Hudis, C.; Modi, S., A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clin Breast Cancer 2013
25. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068-77
26. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13:152
27. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-17
28. Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, Potter D, Ivy SP, Murgo AJ, Ramanathan RK (2004) Comparison of child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing. In J Clin Oncol 22:14s, (suppl;abst 6051), 2004
29. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-15
30. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D (2013) Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 71:1345-55
31. Strassburg CP, Kalthoff S, Ehmer U (2008) Variability and function of family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A). Crit Rev Clin Lab Sci 45:485-530
32. Acquaviva, J.; He, S.; Zhang, C.; Jimenez, J. P.; Nagai, M.; Sang, J.; Sequeira, M.; Smith, D. L.; Shin Ogawa, L.; Inoue, T.; Tatsuta, N.; Knowles, M. A.; Bates, R. C.; Proia, D. A., FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism. Mol Cancer Res 2014
33. Strassburg CP, Oldhafer K, Manns MP, Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212-20
34. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-10
35. Ramalingam, S., GD; Andric, Z.; Bondarenko, I.; Zaric, B.; Ceric, T.; al., e., A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). In ASCO, J Clin Oncol 31, s.; CRA8007), a., Eds. Chicago, 2013
36. Guo, W.; Yan, L.; Yang, L.; Liu, X.; E, Q.; Gao, P.; Ye, X.; Liu, W.; Zuo, J., Targeting GRP75 Improves HSP90 Inhibitor Efficacy by Enhancing p53-Mediated Apoptosis in Hepatocellular Carcinoma. PLoS One 2014, 9, e85766
37. Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, Zhou W (2013) Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget 4:816-29